title: Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
abstract: We describe the clinical outcome of 17 patients with secondary Acinetobacter bacteremia whose isolates had a tigecycline MIC of ≤2 mg/liter and who received tigecycline within 2 days of bacteremia onset. The 14-day mortality rate of the tigecycline cohort was 41.2% (7/17), which was significantly higher than that of those receiving other appropriate antimicrobial agents (13.8%, 9/65; P = 0.018). However, the percentages of end-stage renal disease and congestive heart failure were higher in the tigecycline cohort. The efficacy of tigecycline was contingent upon the illness severity and bacterial species. Tigecycline should be applied cautiously for treatment of Acinetobacter bacteremia.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu City, Taiwan.
authors.forename: Bo-Huang
authors.initials: BH
authors.lastname: Liou
authors.affiliation: Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
authors.forename: Yi-Tzu
authors.initials: YT
authors.lastname: Lee
authors.affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan ludwigvantw@gmail.com.
authors.forename: Shu-Chen
authors.initials: SC
authors.lastname: Kuo
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
authors.forename: Po-Yu
authors.initials: PY
authors.lastname: Liu
authors.affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
authors.forename: Chang-Phone
authors.initials: CP
authors.lastname: Fung
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology*; D040981:Acinetobacter baumannii / Q000187:drug effects / Q000472:pathogenicity; D016954:Acinetobacter calcoaceticus / Q000187:drug effects / Q000472:pathogenicity; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline
references.citation: Diagn Microbiol Infect Dis. 2008 Jul;61(3):329-38
references.pmid: 18508226
references.citation: Clin Infect Dis. 2010 Jan 15;50(2):229-38
references.pmid: 20025527
references.citation: Clin Microbiol Infect. 2011 Dec;17(12):1798-803
references.pmid: 21595793
references.citation: J Antimicrob Chemother. 2011 Aug;66(8):1839-46
references.pmid: 21653602
references.citation: Clin Infect Dis. 2011 Feb 1;52(3):352-60
references.pmid: 21193494
references.citation: Clin Infect Dis. 2012 Jul;55(2):209-15
references.pmid: 22495546
references.citation: Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53
references.pmid: 16080072
references.citation: Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67
references.pmid: 16080073
references.citation: Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61
references.pmid: 18990531